A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT ID: NCT00570986
Last Updated: 2013-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1465 participants
INTERVENTIONAL
2007-11-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00691964
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00710580
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00292396
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
NCT00679731
Open Label Continuation Study in Moderate to Severe Psoriasis
NCT00626002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Arm #1 is used for entire study. At week 12, arm is rerandomized.
Placebo
Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
2
Arm #2 is used for entire study. At week 12, arm is rerandomized.
ABT-874
200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
3
Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
ABT-874
100mg every 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
ABT-874
200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
ABT-874
100mg every 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
* Subject is judged to be in generally good health as determined by the principal investigator
Exclusion Criteria
* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
* Subject is taking or requires oral or injectible corticosteroids
* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis
* Subject considered by the investigator, for any reason, to be an unsuitable candidate
* Female subject who is pregnant or breast-feeding or considering becoming pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Kaul, MD
Role: STUDY_CHAIR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 6579
Birmingham, Alabama, United States
Site Reference ID/Investigator# 6697
Birmingham, Alabama, United States
Site Reference ID/Investigator# 7015
Huntsville, Alabama, United States
Site Reference ID/Investigator# 6728
Scottsdale, Arizona, United States
Site Reference ID/Investigator# 6584
Tucson, Arizona, United States
Site Reference ID/Investigator# 6696
Little Rock, Arkansas, United States
Site Reference ID/Investigator# 6591
Bakersfield, California, United States
Site Reference ID/Investigator# 6710
Fresno, California, United States
Site Reference ID/Investigator# 7885
Irvine, California, United States
Site Reference ID/Investigator# 6872
Los Angeles, California, United States
Site Reference ID/Investigator# 7669
Oceanside, California, United States
Site Reference ID/Investigator# 6821
San Diego, California, United States
Site Reference ID/Investigator# 6832
San Diego, California, United States
Site Reference ID/Investigator# 7305
San Diego, California, United States
Site Reference ID/Investigator# 7990
San Francisco, California, United States
Site Reference ID/Investigator# 6711
Santa Monica, California, United States
Site Reference ID/Investigator# 8139
Torrance, California, United States
Site Reference ID/Investigator# 7167
Vallejo, California, United States
Site Reference ID/Investigator# 7302
Denver, Colorado, United States
Site Reference ID/Investigator# 6921
Longmont, Colorado, United States
Site Reference ID/Investigator# 6917
New Haven, Connecticut, United States
Site Reference ID/Investigator# 6707
Jacksonville, Florida, United States
Site Reference ID/Investigator# 7301
Miami, Florida, United States
Site Reference ID/Investigator# 7012
Miami, Florida, United States
Site Reference ID/Investigator# 6831
Miami, Florida, United States
Site Reference ID/Investigator# 7016
South Miami, Florida, United States
Site Reference ID/Investigator# 6590
West Palm Beach, Florida, United States
Site Reference ID/Investigator# 6582
Alpharetta, Georgia, United States
Site Reference ID/Investigator# 7450
Atlanta, Georgia, United States
Site Reference ID/Investigator# 6714
Newnan, Georgia, United States
Site Reference ID/Investigator# 6717
Snellville, Georgia, United States
Site Reference ID/Investigator# 7017
Arlington Heights, Illinois, United States
Site Reference ID/Investigator# 7877
Maywood, Illinois, United States
Site Reference ID/Investigator# 6704
Skokie, Illinois, United States
Site Reference ID/Investigator# 7292
West Dundee, Illinois, United States
Site Reference ID/Investigator# 6706
Indianapolis, Indiana, United States
Site Reference ID/Investigator# 7646
Indianapolis, Indiana, United States
Site Reference ID/Investigator# 7014
Overland Park, Kansas, United States
Site Reference ID/Investigator# 6873
Louisville, Kentucky, United States
Site Reference ID/Investigator# 7523
Owensboro, Kentucky, United States
Site Reference ID/Investigator# 6597
Andover, Massachusetts, United States
Site Reference ID/Investigator# 6703
Boston, Massachusetts, United States
Site Reference ID/Investigator# 7644
Detroit, Michigan, United States
Site Reference ID/Investigator# 6826
Fort Gratiot, Michigan, United States
Site Reference ID/Investigator# 7989
Grand Blanc, Michigan, United States
Site Reference ID/Investigator# 6581
Fridley, Minnesota, United States
Site Reference ID/Investigator# 7890
St Louis, Missouri, United States
Site Reference ID/Investigator# 6709
St Louis, Missouri, United States
Site Reference ID/Investigator# 7451
Omaha, Nebraska, United States
Site Reference ID/Investigator# 7299
Berlin, New Jersey, United States
Site Reference ID/Investigator# 6924
East Windsor, New Jersey, United States
Site Reference ID/Investigator# 6577
New Brunswick, New Jersey, United States
Site Reference ID/Investigator# 7030
Albuquerque, New Mexico, United States
Site Reference ID/Investigator# 7878
Buffalo, New York, United States
Site Reference ID/Investigator# 7876
New York, New York, United States
Site Reference ID/Investigator# 6599
New York, New York, United States
Site Reference ID/Investigator# 6895
New York, New York, United States
Site Reference ID/Investigator# 7637
New York, New York, United States
Site Reference ID/Investigator# 7504
Rochester, New York, United States
Site Reference ID/Investigator# 7018
Stoney Brook, New York, United States
Site Reference ID/Investigator# 6926
Hickory, North Carolina, United States
Site Reference ID/Investigator# 7293
Wilmington, North Carolina, United States
Site Reference ID/Investigator# 8251
Winston-Salem, North Carolina, United States
Site Reference ID/Investigator# 6598
Cincinnati, Ohio, United States
Site Reference ID/Investigator# 8082
Cleveland, Ohio, United States
Site Reference ID/Investigator# 7165
Columbus, Ohio, United States
Site Reference ID/Investigator# 7659
Dayton, Ohio, United States
Site Reference ID/Investigator# 6727
Lake Oswego, Oregon, United States
Site Reference ID/Investigator# 6894
Portland, Oregon, United States
Site Reference ID/Investigator# 6578
Portland, Oregon, United States
Site Reference ID/Investigator# 7295
Portland, Oregon, United States
Site Reference ID/Investigator# 7879
Hershey, Pennsylvania, United States
Site Reference ID/Investigator# 6712
Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 6580
Johnston, Rhode Island, United States
Site Reference ID/Investigator# 6576
Providence, Rhode Island, United States
Site Reference ID/Investigator# 6589
Greer, South Carolina, United States
Site Reference ID/Investigator# 6586
Goodlettsville, Tennessee, United States
Site Reference ID/Investigator# 7668
Knoxville, Tennessee, United States
Site Reference ID/Investigator# 6915
Nashville, Tennessee, United States
Site Reference ID/Investigator# 6825
Arlington, Texas, United States
Site Reference ID/Investigator# 6762
Austin, Texas, United States
Site Reference ID/Investigator# 6822
Dallas, Texas, United States
Site Reference ID/Investigator# 7671
Dallas, Texas, United States
Site Reference ID/Investigator# 6705
Houston, Texas, United States
Site Reference ID/Investigator# 6708
San Antonio, Texas, United States
Site Reference ID/Investigator# 7081
San Antonio, Texas, United States
Site Reference ID/Investigator# 6912
Tyler, Texas, United States
Site Reference ID/Investigator# 7306
Webster, Texas, United States
Site Reference ID/Investigator# 8101
Salt Lake City, Utah, United States
Site Reference ID/Investigator# 6807
Norfolk, Virginia, United States
Site Reference ID/Investigator# 6801
Seattle, Washington, United States
Site Reference ID/Investigator# 7519
Spokane, Washington, United States
Site Reference ID/Investigator# 7080
Milwaukee, Wisconsin, United States
Site Reference ID/Investigator# 7314
Barrie, , Canada
Site Reference ID/Investigator# 7452
Calgary, , Canada
Site Reference ID/Investigator# 6702
Edmonton, , Canada
Site Reference ID/Investigator# 6716
Halifax, , Canada
Site Reference ID/Investigator# 7309
Hamilton, , Canada
Site Reference ID/Investigator# 6588
Laval, , Canada
Site Reference ID/Investigator# 6715
London, , Canada
Site Reference ID/Investigator# 7315
London, , Canada
Site Reference ID/Investigator# 7636
Markham, , Canada
Site Reference ID/Investigator# 6699
Montreal, , Canada
Site Reference ID/Investigator# 7316
Montreal, , Canada
Site Reference ID/Investigator# 7088
North Bay, , Canada
Site Reference ID/Investigator# 7310
Ottawa, , Canada
Site Reference ID/Investigator# 7311
Québec, , Canada
Site Reference ID/Investigator# 7313
St. John's, , Canada
Site Reference ID/Investigator# 7317
Surrey, , Canada
Site Reference ID/Investigator# 7308
Vancouver, , Canada
Site Reference ID/Investigator# 6713
Vancouver, , Canada
Site Reference ID/Investigator# 7067
Waterloo, , Canada
Site Reference ID/Investigator# 7312
Westmount, , Canada
Site Reference ID/Investigator# 7087
Windsor, , Canada
Site Reference ID/Investigator# 6805
Windsor, , Canada
Site Reference ID/Investigator# 7638
Winnipeg, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M06-890
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.